Lacerol Retard is generally used across domains where additional symptomatic support is needed. This medication is applied in managing conditions presenting with heightened symptoms, specifically hypertension, chronic stable angina, angina due to coronary artery spasm, and certain supraventricular tachycardias.

---

Sustained Management and Symptom Relief

The medicine is commonly used for conditions characterized by persistent elevated vascular pressure and recurrent ischemia-related chest discomfort. For hypertension, it is commonly used for managing symptoms related to systemic imbalance that often accompany elevated vascular pressure, and is relevant for easing the overall symptom load associated with cardiovascular conditions. For angina, it may assist with managing recurrent episodes, contributes to easing physical discomfort during periods of exertion. The therapeutic benefit extends to specific rapid heart rhythm disorders, where it is relevant for easing symptoms related to heightened physiological activity that affect heart rhythm, which assists with managing symptomatic manifestations associated with a fast, irregular rhythm.

“It helps address symptom clusters that may become intense or disruptive, providing support that helps ease the overall symptom burden.”

This long-term use is relevant when supportive symptom management is appropriate and may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Key Symptom Domains
Primary Focus	Managing elevated vascular pressure and easing symptoms related to recurrent chest discomfort.
Symptom Easing	Eases symptoms related to systemic imbalance (high BP) and physical discomfort (angina).
Practical Benefit	Contributes to easing day-to-day discomfort and supports functional stability.

Regulatory References

1. DailyMed Labeling Information from the NIH

The eligibility for using Lacerol Retard (Diltiazem prolonged-release) is strictly governed by pre-existing medical conditions, particularly those related to the heart, as specified in government regulatory documents.

Eligibility Scope

Category	Regulatory Status
Populations for whom use is allowed	Adults for the management of approved cardiovascular conditions.
Populations for whom use is not recommended	Pediatric patients (safety and effectiveness have not been established). Women of child-bearing potential not using effective contraception.
Populations for whom use is contraindicated	Patients with Sick Sinus Syndrome (unless a functioning ventricular pacemaker is present). Patients with Second- or Third-Degree AV Block (unless a functioning ventricular pacemaker is present). Patients with Hypotension (systolic blood pressure less than 90 mm Hg). Patients with Acute Myocardial Infarction and accompanying Pulmonary Congestion. Patients with Atrial Fibrillation/Flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White Syndrome).

Condition-Specific Eligibility Rules

• Impaired Organ Function: Use with caution is advised for patients with Impaired Hepatic Function or Impaired Renal Function.
• Cardiac Function: Use with caution in patients with Reduced Left Ventricular Function or Congestive Heart Failure.
• Pregnancy and Lactation: Use is not recommended or contraindicated during pregnancy. During lactation, use is avoided as the drug is excreted in human milk, and a decision must be made to discontinue nursing or discontinue the drug.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Lacerol Retard by establishing a set of absolute exclusions based on severe, pre-existing cardiac conditions. Use is also restricted in pediatric and reproductive populations due to lack of established safety or documented risk, and conditional use is specified for patients with impaired organ function.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Lacerol Retard (diltiazem) based on its documented role as a moderate inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. This pharmacokinetic interaction pattern increases the systemic exposure of many co-administered medicines that are substrates for these pathways.

Documented Interaction Patterns

Interaction Type	Examples of Affected Medicines
Increased Exposure (PK interaction)	Statins (e.g., Simvastatin), Immunosuppressants (e.g., Ciclosporin), Anticoagulants (e.g., Rivaroxaban)
Additive Cardiac Effects (PD interaction)	Beta-blockers, Digoxin, Halogenated Anesthetics
Decreased Diltiazem Exposure	CYP3A4 Inducers (e.g., Rifampicin, Apalutamide)

Co-administration with other cardiac agents, such as Beta-blockers, carries a documented risk of additive negative chronotropic and dromotropic effects, requiring adherence to established constraints. The combination of diltiazem and Colchicine is strictly prohibited in patients with pre-existing renal or hepatic impairment. Furthermore, specific sustained-release formulations caution against the concurrent use of alcoholic beverages due to the potential for altered absorption. Grapefruit juice is documented to slightly increase diltiazem’s systemic exposure.

The action of Lacerol Retard (Diltiazem) is a targeted pharmacodynamic intervention that simultaneously addresses key components of cardiovascular regulation by inhibiting the movement of calcium ions. This dual activity contributes to the drug's physiological effect profile.

Modulation of Cardiac Electrical Conduction

Its primary mechanism involves the blockade of L-type voltage-gated calcium channels ( CaV1) in the heart's specialized electrical tissues, specifically the Sinoatrial ( SA) and Atrioventricular ( AV) nodes. Restricting the Ca^2+ influx required for signal generation and transmission slows the heart's natural pacemaker rate and prolongs the time taken for electrical signals to pass through the AV node. This results in the physiological effects of slowing heart rate (negative chronotropy) and delaying cardiac conduction (negative dromotropy).

Regulation of Arterial Tone and Resistance

Diltiazem simultaneously applies the same CaV1 channel blockade mechanism to the smooth muscle cells within the walls of arteries. The inhibition of Ca^2+ entry prevents the activation of the cellular contractile machinery, leading to the relaxation of the muscle (vasodilation). This arterial relaxation reduces the physical pressure encountered by blood flowing through the circulation, resulting in decreased Systemic Vascular Resistance (SVR).

Reduction of Myocardial Workload

The combined mechanistic cascade—reduced SVR, slower rate, and decreased contractility (negative inotropy)—results in reduced cardiovascular workload.

How to Use Lacerol Retard: Official Administration Guidelines

Lacerol Retard, a prolonged-release formulation of diltiazem hydrochloride, is administered exclusively via the oral route, consistent with its design as an extended-release solid form, such as a tablet or capsule.

---

Standard Dosing and Administration

This medication is typically taken once daily at approximately the same time each day. The prolonged-release form must be swallowed whole and must not be crushed or chewed to preserve its intended 24-hour drug release profile. Administration may be taken without regard to food, though this instruction can vary by specific formulation.

Indication	Initial Dose (Once Daily)	Maintenance Dose Range
Hypertension	180 mg to 240 mg	180 mg to 540 mg
Angina Pectoris	120 mg to 180 mg	Dose adjusted as necessary

Dosage adjustment, or titration, is a gradual process. Changes in the daily dose are typically implemented at intervals of 7 to 14 days to allow sufficient time for the extended-release formulation to achieve its maximum therapeutic effect before further increases are considered.

---

Population-Specific Use

Older adults and patients with renal or hepatic impairment require particular care. For these groups, therapy should commence at the lowest end of the dosing range, and any subsequent adjustment must be made slowly and carefully. This medication is not recommended for use in children, as its safety and efficacy have not been established in the pediatric population.

If a dose is missed, patients are generally instructed not to take a double dose and should instead resume the scheduled once-daily regimen at the usual time.

Lacerol Retard: Recent Clinical Evidence

This section provides an overview of the clinical research and scientific studies that have evaluated Lacerol Retard (diltiazem prolonged-release). This information is based on findings reported by regulatory bodies and peer-reviewed scientific literature.

---

Research Context: Essential Hypertension

Research exploring Lacerol Retard in the context of essential hypertension primarily consists of short-term, placebo-controlled Randomized Controlled Trials (RCTs). The studies measured intermediate endpoints, such as tracking blood pressure levels (diastolic and systolic measurements) and assessing the consistency of 24-hour blood pressure levels in adults with mild-to-moderate hypertension. Findings describe patterns observed in these blood pressure measurements. The evidence is largely derived from these multiple, short-term RCTs.

---

Research Context: Chronic Stable Angina

For chronic stable angina, studies explored outcomes related to physical discomfort and daily functioning. The evidence comes from short- to intermediate-term RCTs involving adult patients with stable effort-induced angina. Studies monitored functional measures like exercise tolerance time (ETT), time to the onset of chest pain, and the frequency of anginal episodes. These findings help contextualize how patients reported their experience during exertion.

---

Research Gaps and Extended Follow-up

A critical research limitation across both indications is the limited duration of the core efficacy trials. The primary evidence base relies heavily on intermediate measures (blood pressure and exercise time) rather than direct observation of long-term outcomes like the prevention of heart attack or stroke. Research exploring the long-term impact on major cardiovascular events is not fully characterized by the primary regulatory evidence base. Furthermore, data for certain subgroups, such as children, remain insufficient.

Key Studies & References

1. Diltiazem Hydrochloride Extended-Release Capsules, USP Labeling Information (NIH DailyMed)

Common questions about Lacerol Retard (FAQ)

---

Q: What is the difference between Lacerol and Lacerol Retard?

Lacerol Retard is a prolonged-release formulation, designed to be taken once daily to maintain consistent levels of the active medicine over a full 24-hour period. In contrast, the standard, immediate-release (IR) version has a shorter duration of action, which typically requires it to be taken several times throughout the day.

Q: What are the main conditions Lacerol Retard is prescribed for?

According to official product information, this medicine is indicated for managing high blood pressure (hypertension). It is also prescribed for treating and preventing symptoms of angina pectoris, which is chest pain caused by reduced blood flow to the heart muscle.

Q: Does Lacerol Retard work immediately after taking it?

As an extended-release medicine, the active ingredient is released slowly into the bloodstream. Detectable levels are seen in the blood within a few hours. However, the maximum blood pressure-lowering effect is often achieved after a period of consistent daily use, generally noted in clinical studies around two weeks.

Q: Is Lacerol Retard known to cause drowsiness or affect alertness?

Official documents list side effects such as dizziness and fatigue as possible. Due to the possibility of these effects, regulatory documents recommend that a person should exercise caution when performing skilled tasks such as driving or operating machinery.

Q: Are there any known food restrictions while using Lacerol Retard?

The medicine is generally administered without regard to food (with or without a meal), though this can vary slightly by specific formulation. Regulatory information indicates caution is advised regarding certain products, such as grapefruit, which have the potential to interfere with the drug's metabolism.

Q: What kind of research has been done on Lacerol Retard?

The effectiveness and safety of the drug have been studied in controlled clinical trials. These studies primarily evaluate the ability of the medication to effectively manage essential hypertension and to measure improvements in exercise tolerance for people with chronic stable angina.

Q: Are there different strengths of Lacerol Retard available?

Diltiazem extended-release products are typically manufactured in a range of strengths to allow for personalized adjustment. Common strengths include tablets or capsules ranging from 120 mg up to 420 mg.

Q: Is Lacerol Retard a maintenance treatment or a short-term treatment?

Official product information indicates that Lacerol Retard is designed as a maintenance treatment for chronic conditions like hypertension and angina. It is typically intended for use over an extended period to sustain therapeutic benefits.

Q: Does Lacerol Retard interact with supplements like vitamins or herbal products?

The medicine can influence how the body processes other substances because it affects a specific enzyme system in the liver (CYP3A4). Official guidance emphasizes that caution is necessary when the drug is co-administered with products, including certain herbal remedies or supplements, that affect this enzyme pathway.

Q: Is there any evidence about Lacerol Retard use during pregnancy or breastfeeding?

Official documentation often describes that the use of this drug during breastfeeding is generally to be avoided, as the active substance has been detected in breast milk. Regulatory bodies may also advise against use during pregnancy due to findings of developmental toxicity in animal studies.

Q: Do I need a prescription from a doctor to get Lacerol Retard?

Yes, Lacerol Retard (diltiazem hydrochloride) is consistently classified by official drug agencies as a prescription-only medicine for use in humans. Its classification requires it to be obtained with a prescription.

Q: Is it normal to feel a mild stomach upset when first taking Lacerol Retard?

Official documents list gastrointestinal disturbances as possible side effects. Because this medication can influence movement within the digestive tract, its use is sometimes noted with caution in official documents for patients with pre-existing risks of intestinal issues.

Q: Are there long-term studies on the effects of Lacerol Retard?

Yes, the drug is indicated for chronic conditions like hypertension. Clinical studies evaluate its effects over extended periods, and the therapeutic benefit includes a recognized role in reducing the long-term risk of cardiovascular events associated with these chronic diseases.

Q: What are the warning signs for a serious reaction to Lacerol Retard?

Official warnings focus on pre-existing heart conditions. The medicine is contraindicated (not to be used) in the presence of certain heart rhythm disorders, such as second- or third-degree AV block, or conditions like very low blood pressure.

Q: Does Lacerol Retard have any known effects on mental clarity or focus?

Official product information has noted that calcium channel blockers, such as diltiazem, are associated with potential mood changes. This includes reports linking the use of the drug to feelings of depression.

Q: Can people who drive or operate machinery take Lacerol Retard?

Official documents describe that, due to potential effects like dizziness and fatigue, caution may be necessary when performing skilled tasks such as driving or operating machinery.

Q: Can Lacerol Retard be taken on an empty stomach?

Whether the drug is best taken on an empty or full stomach depends on the exact formulation used. Some versions are designed to be taken without regard to food, while for others, specific recommendations may exist to maximize absorption.

Q: What types of allergic reactions are possible with Lacerol Retard?

The primary safety warning regarding allergic reactions is the contraindication for patients with a known hypersensitivity (allergy) to the active substance or any of the inactive ingredients in the tablet or capsule.

Q: What does official guidance say about taking Lacerol Retard with dairy products?

The official guidance on administration generally states that Lacerol Retard can be taken without regard to food. This implies that specific dietary components like dairy products do not typically require a special restriction, although this may vary by specific commercial formulation.

Q: What is the general overview of the safety profile of Lacerol Retard?

The safety profile is based on clinical data regarding side effects and contraindications. The most significant warnings relate to use in people with specific pre-existing cardiovascular issues, such as severe low blood pressure or certain electrical conduction defects in the heart.

Q: Can Lacerol Retard cause changes in mood?

Yes, regulatory product documents note that this class of medication is associated with mood changes. Specifically, there have been official reports linking the use of diltiazem to feelings of depression.

Q: What is the half-life of Lacerol Retard?

The half-life refers to the time it takes for half of the drug to be eliminated from the body. For the extended-release formulation, the apparent elimination half-life is typically reported to be approximately 6 to 9 hours.

Q: What information should I know about drug interactions before taking Lacerol Retard?

The drug can increase the effects of certain other medications, particularly those that also slow the heart rate (like beta-blockers) or those that are broken down by the CYP3A4 enzyme system. This may lead to increased concentrations of co-administered medicines, such as certain statins.

Q: Can Lacerol Retard cause issues with sleeping?

While the drug is not listed as a sleep aid, side effects like fatigue and other central nervous system effects are reported in official documents. These effects can potentially cause or interfere with a person's normal sleep patterns.

Q: How long does it typically take to start noticing the effects of Lacerol Retard?

Clinical studies often report that the maximum blood pressure-lowering effect is achieved after a period of chronic therapy, frequently noted around 14 days. This is the time needed for the extended-release formula to reach and maintain steady concentrations in the body.

Q: Is Lacerol Retard safe to take if I have liver disease?

Official documentation notes that because the medicine is processed by the liver, patients with impaired liver function require specific caution and monitoring is often advised. Official guidelines describe that in cases of impairment, therapy may be started at the lower end of the dosing range.

Q: Is it typical for doctors to prescribe Lacerol Retard for extended periods?

Yes, this medicine is indicated for managing chronic, long-term conditions like hypertension and angina pectoris. The maintenance dosing schedules in official product information are designed for use over an extended period.

Q: What is the duration of action for Lacerol Retard compared to the immediate release form?

The Lacerol Retard extended-release formulation is specifically designed to provide and maintain therapeutic drug concentrations over a 24-hour period. This allows for a convenient once-daily dosing compared to the shorter duration of action of the immediate-release form.

Q: Do I have to take Lacerol Retard at a specific time of day?

Clinical administration guidelines state that the medicine should be taken once daily at approximately the same time each day. Studies indicate the drug can be taken consistently in either the morning or the evening.

The storage and disposal of Lacerol Retard (diltiazem hydrochloride prolonged-release) must conform to the mandated conditions established by regulatory authorities.

Storage Conditions

Requirement	Official Statement
Temperature Range	Store at 25 C (77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).
Environmental Protection	Must be protected from excessive humidity and should be dispensed in a light-resistant container.
Container Rule	Keep the container tightly closed when not in use.

Handling and Disposal

Official labeling requires that the medication be stored out of the reach of children. Unused or expired product must be disposed of after the expiration date and according to local regulations. Health authorities often recommend utilizing a drug take-back program for safe disposal.